Comparing fexuprazan and rabeprazole for treating peptic ulcer: A multicenter, randomized controlled trial

Table 2 Absolute risk differences of ulcer healing rates at week 4 and week 8, n (%)

Analysis set	Time point	Fexuprazan 40 mg	Rabeprazole 20 mg	Difference (95%CI)	P value1
Per protocol set	8 weeks	51/51 (100)	50/51 (98.04)	1.96 (-1.84 to 5.77)	< 0.0001
	4 weeks	50/51 (98.04)	48/51 (94.12)	3.92 (-3.57 to 11.42)	0.0001
Full analysis set	8 weeks	51/52 (98.08)	50/51 (98.04)	0.04 (-5.29 to 5.37)	0.0001
	4 weeks	50/52 (96.15)	48/51 (94.12)	2.04 (-6.27 to 10.34)	0.0023

¹Non-inferiority test.

Difference = fexuprazan – rabeprazole. The 95%CI was calculated by Wald method. In all analyses, the lower limit of the 95%CI exceeded the non-inferiority margin of -10%.